Neuroone Medical Technologies (NMTC) Current Deferred Revenue (2020 - 2022)

Neuroone Medical Technologies (NMTC) has reported Current Deferred Revenue for 3 consecutive years, with $1.5 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Current Deferred Revenue rose 16777.62% year-over-year to $1.5 million; the trailing twelve-month figure through Sep 2022 stood at $1.5 million (up 16777.62% YoY), and the FY2022 full-year result was $1.5 million, up 16777.62% from the prior year.
• Current Deferred Revenue climbed to $1.5 million in Q3 2022 per NMTC's latest filing, from $2248.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.5 million in Q3 2022 and bottomed at $2248.0 in Q4 2021.
• Historically, Current Deferred Revenue has averaged $182199.0 across 3 years, with a median of $13596.0 in 2021.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue slumped 95.61% in 2021, then surged 16777.62% in 2022.
• Over 3 years, Current Deferred Revenue stood at $51160.0 in 2020, then plunged by 95.61% to $2248.0 in 2021, then jumped by 64632.56% to $1.5 million in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.5 million, $2248.0, and $2248.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.